Assessing the Relationship Between Antigenicity and Immunogenicity of Human Rabies Vaccines

被引:13
作者
Sudarshan, M. K. [1 ,2 ]
Mahendra, B. J. [1 ,2 ]
Madhusudana, S. N. [3 ]
Narayana, D. H. Ashwath [1 ,2 ]
Sanjay, T. V. [1 ,2 ]
Gangaboraiah [1 ,2 ]
Anandagiri, M. S. [1 ,2 ]
机构
[1] Kempegowda Inst Med Sci, Dept Community Med, Bangalore 560004, Karnataka, India
[2] Kempegowda Inst Med Sci, Rabies Epidemiol Unit, Bangalore 560004, Karnataka, India
[3] Natl Inst Mental Hlth & Neurosci, Dept Neurovirol, Bangalore 560029, Karnataka, India
来源
HUMAN VACCINES | 2005年 / 1卷 / 05期
关键词
rabies; rabies vaccines; vaccine potency; vaccine trial; meta-analysis;
D O I
10.4161/hv.1.5.2110
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
A meta-analysis was done to study the relationship between antigenecity and immunogenecity of human rabies vaccines. The data of ten cell culture human rabies vaccine studies conducted at a single centre during 1993-2004 were used in the study. The vaccines studied included Purified Chick Embryo Cell Vaccine (Kaketsuken, Japan and Rabipur, India), Purified Vero cell Rabies Vaccine (Verorab, France), Human Diploid Cell Vaccine (MIRV, France and Rabivax, Adsorbed and Lyophilized, India) and Rhesus Diploid Rabies Vaccine (adsorbed, USA). Interestingly, it was revealed that an higher antigenecity of rabies vaccines viz. potency of >= 5 IU per single intramuscular dose did not result in significantly higher immunogenecity, as measured by rabies virus neutralizing antibody (RVNA) titers in the vaccinees, both on day14(t = 0.42, p > 0.66, GMR = 1.06, 95% CI of GMR = 0.82, 1.37) and day 90 (t = 0.80, p > 0.43, GMR = 1.15, 95% CI of GMR = 0.74, 1.14). However, as there are no reports of meta-analysis of cell culture human rabies vaccine trials, to confirm this observation the authors recommend further studies in this regard.
引用
收藏
页码:187 / 190
页数:4
相关论文
共 5 条
[1]  
[Anonymous], 2004, RAB SCI MON
[2]  
Meslin F-X, 1996, LAB TECHNIQUES RABIE
[3]  
Sudarshan M K, 2004, ASSESSING BURDEN RAB
[4]  
Warell M J, 2000, WHOCASCSRAPH20005
[5]  
*WHO, 2005, TECHN REP SER WHO, V931